What did @geniuslyhealth actually say?
The creator made three distinct claims about BPC-157: that it promotes angiogenesis (new blood vessel formation) at injury sites, that it stimulates fibroblast migration and proliferation, and that these effects can restore torn or partially torn tendons and ligaments to a "complete" state. These are specific, mechanistic claims, not vague wellness talk, and they deserve a specific, mechanistic response.
The framing matters here. The creator repeatedly anchors their claims to animal studies, which is a meaningful caveat, but they slide from "animal studies show" into stating outcomes like restored tendons as if they were settled clinical results. That gap between rodent data and human outcomes is where most of the controversy lives.
Does the science back this up?
Partially, yes, and more than you might expect for a peptide this far from FDA approval. The angiogenesis and fibroblast claims are genuinely supported by preclinical literature.
On angiogenesis: Chang et al. (2011, Journal of Applied Physiology) demonstrated that BPC-157 upregulates VEGF expression and accelerates capillary formation in rat tendon injury models. The "calls in and promotes" framing the creator uses is a loose but not inaccurate description of that dual signaling effect.
On fibroblasts: Staresinic et al. (2003, Journal of Orthopaedic Research) showed BPC-157 significantly increased fibroblast migration in vitro and improved tendon healing in a rat transection model. The effect on collagen organization was real and measurable. So the creator is citing real phenomena, just from animal data that has not been replicated in randomized controlled human trials.
What did they get wrong (or right)?
They got the mechanisms mostly right. The angiogenesis pathway and fibroblast involvement in connective tissue repair are legitimate science, not invented. Credit where it is due.
What they got wrong is the leap to clinical outcome. Saying BPC-157 can restore a tendon "from torn or partially torn to a complete tendon or ligament" is not supported by human evidence. That is a therapeutic outcome claim with zero published human RCT data behind it. The preclinical data is promising, not conclusive.
There is also a meaningful omission: BPC-157 is not FDA-approved, has been subject to FDA compounding restrictions, and its pharmacokinetics in humans are poorly characterized. A 92,000-view video describing near-complete tendon repair without those disclosures is, at minimum, incomplete. Brkic et al. (2022, Current Pharmaceutical Design) reviewed the existing literature and concluded that while mechanistic evidence is strong in animals, translational evidence in humans remains absent.
What should you actually know?
BPC-157 is a synthetic peptide derived from a protective gastric protein. It is not approved for human use by the FDA. It has never completed a Phase III clinical trial. The healing effects described in this video, while based on real animal research, have not been proven to occur in humans at any dose through any route of administration.
That does not mean the science is fake. It means we are at a stage of research where enthusiasm routinely outruns evidence. The fibroblast and angiogenesis data are real signals worth investigating. But anyone considering BPC-157 for a torn tendon should understand they are acting on rat data, not clinical proof.
If you are dealing with a tendon or ligament injury, evidence-based options like physical therapy, PRP in selected cases, and surgical repair for complete tears have actual human trial data behind them. BPC-157 may one day join that list. It is not there yet.